Table 3 GRADE assessment
Certainty assessment | No. of patients | Certainty | Importance | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
Intervention of studies | Study design | Risk of bias | Inconsistency | Indirectness | Imprecision | Publication bias | Intervention group | Control group | ||
MACE (No. of studies: 16) | CRITICAL | |||||||||
 SGLT2i vs Placebo | Randomised trials | Not serious | Not serious | Not serious | Not serious | None | 1255/13143 (9.5%) | 1266/11688 (10.8%) | High |  |
 GLP-1 RA vs Placebo | Randomised trials | Not serious | Not serious | Not serious | Not serious | None | 740/6045 (12.2%) | 795/5344 (14.9%) | High |  |
 Finerenone vs Placebo | Randomised trials | Not serious | Not serious | Not serious | Not serious | None | 686/6519 (10.5%) | 777/6507 (11.9%) | High |  |
Renal outcome (No. of studies: 13) | Â | CRITICAL | ||||||||
 SGLT2i vs Placebo | Randomised trials | Not serious | Not serious | Not serious | Not serious | None | 586/11731 (5.0%) | 700/10981 (6.4%) | High |  |
 GLP-1 RA vs Placebo | Randomised trials | Not serious | Not serious | Not serious | Not serious | None | 428/3754 (11.4%) | 474/3780 (12.5%) | High |  |
 Finerenone vs Placebo | Randomised trials | Not serious | Not serious | Not serious | Not serious | None | 861/7234 (11.9%) | 997/6600 (15.1%) | High |  |
HHF (No. of studies: 12) | Â | IMPORTANT | ||||||||
 SGLT2i vs Placebo | Randomised trials | Not serious | Not serious | Not serious | Not serious | None | 395/13144 (3.0%) | 561/11689 (4.8%) | High |  |
 GLP-1 RA vs Placebo | Randomised trials | Not serious | Not serious | Not serious | Not serious | None | 174/2673 (6.5%) | 191/2662 (7.2%) | High |  |
 Finerenone vs Placebo | Randomised trials | Not serious | Not serious | Not serious | Not serious | None | 256/6519 (3.9%) | 325/6507 (5.0%) | High |  |
ACD (No. of studies: 11) | IMPORTANT | |||||||||
 SGLT2i vs Placebo | Randomised trials | Not serious | Not serious | Not serious | Not serious | None | 706/12128 (5.8%) | 720/10898 (6.6%) | High |  |
 GLP-1 RA vs Placebo | Randomised trials | Not serious | Not serious | Not serious | Not serious | None | 339/2673 (12.7%) | 378/2662 (14.2%) | High |  |
 Finerenone vs Placebo | Randomised trials | Not serious | Not serious | Not serious | Not serious | None | 552/6519 (8.5%) | 614/6507 (9.4%) | High |  |
CVD (No. of studies: 12) | Â | IMPORTANT | ||||||||
 SGLT2i vs Placebo | Randomised trials | Not serious | Not serious | Not serious | Not serious | None | 623/13144 (4.7%) | 597/11689 (5.1%) | High |  |
 GLP-1 RA vs Placebo | Randomised trials | Not serious | Not serious | Not serious | Not serious | None | 213/2673 (8.0%) | 235/2662 (8.8%) | High |  |
 Finerenone vs Placebo | Randomised trials | Not serious | Not serious | Not serious | Not serious | None | 322/6519 (4.9%) | 364/6507 (6.0%) | High |  |